Related Experiment Videos
Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines
H S Chan1, M D Canton, B L Gallie
1Department of Pediatrics, University of Toronto, Ontario, Canada.
Abstract:
Chemosensivity testing in 11 retinoblastoma (RB) cell lines identified five tumors showing cross-resistance to plant alkaloids, alkylating agents, anthracycline antibiotics, and antimetabolites, suggestive of the multidrug-resistant (MDR) phenotype described in other tumors. Only two tumors had been clinically exposed to chemotherapy, and both showed MDR. All RB tumors were resistant to clinically achievable concentrations of methotrexate and hydrocortisone, and only sensitive to cytosine arabinoside. These results provide a rational basis on which to develop new chemotherapeutic strategies for the treatment of RB.
Insights
Chemosensivity testing revealed multidrug resistance (MDR) in retinoblastoma cell lines, with most showing resistance to common chemotherapy agents but sensitivity to cytosine arabinoside, guiding future treatment strategies.
Area of Science:
- Oncology
- Pharmacology
Background:
- Retinoblastoma (RB) is a pediatric eye cancer.
- Understanding drug resistance is crucial for effective RB treatment.
Purpose of the Study:
- To assess the chemosensitivity of retinoblastoma cell lines.
- To identify potential drug resistance patterns in RB tumors.
Main Methods:
- Chemosensivity testing was performed on 11 retinoblastoma cell lines.
- Drug resistance profiles were evaluated against various chemotherapeutic agents.
Main Results:
- Five RB cell lines exhibited multidrug resistance (MDR) phenotypes.
- All tested RB tumors were resistant to methotrexate and hydrocortisone.
- Cytosine arabinoside demonstrated sensitivity across RB cell lines.
Conclusions:
- Retinoblastoma tumors can display MDR, impacting treatment efficacy.
- Cytosine arabinoside shows promise as a therapeutic agent for RB.
- Findings provide a basis for developing novel chemotherapeutic strategies for retinoblastoma.